Spero Therapeutics, Inc.

Contributing Author

Recent Articles by Spero Therapeutics, Inc.

Sep-03	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SPRO GlobeNewswire
Sep-02	Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference SPRO GlobeNewswire
Aug-12	Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update SPRO GlobeNewswire
Aug-05	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SPRO GlobeNewswire
Aug-04	Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 SPRO +6.96% GlobeNewswire
Jul-27	Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer SPRO GlobeNewswire
Jul-14	Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties SPRO -22.02% GlobeNewswire
Jul-14	Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody SPRO -22.02% GlobeNewswire
Jun-17	Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) SPRO -23.83% SPRO +8.06% GlobeNewswire
May-13	Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update SPRO SPRO +13.11% GlobeNewswire
May-05	Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 SPRO GlobeNewswire
Mar-26	Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update SPRO GlobeNewswire
Mar-18	Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 SPRO GlobeNewswire
Dec-19	Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis SPRO GlobeNewswire
Nov-28	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SPRO GlobeNewswire
Nov-13	Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update SPRO -8.27% GlobeNewswire
Nov-04	Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 SPRO GlobeNewswire
Oct-21	PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) SPRO GlobeNewswire
Oct-14	Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek SPRO GlobeNewswire
Aug-12	Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update SPRO +7.27% SPRO -18.01% GlobeNewswire
Aug-05	Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 SPRO -6.19% SPRO +6.60% GlobeNewswire
May-28	Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee SPRO +244.57% GlobeNewswire
May-13	Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update SPRO +13.11% SPRO -5.78% GlobeNewswire
May-05	Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 SPRO -5.72% GlobeNewswire

Spero Therapeutics, Inc.

Recent Articles by Spero Therapeutics, Inc.

Upgrade your Finviz experience